 Bradley Haverkos
Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, T-Cell | 8 | 2024 | 30 | 2.880 |
Why?
| | Lymphoma, T-Cell, Peripheral | 6 | 2024 | 20 | 2.620 |
Why?
| | Lymphoma | 5 | 2023 | 241 | 1.770 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 4 | 2024 | 11 | 1.670 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 6 | 2023 | 45 | 1.610 |
Why?
| | Herpesvirus 4, Human | 6 | 2023 | 172 | 1.460 |
Why?
| | Epstein-Barr Virus Infections | 5 | 2023 | 101 | 1.430 |
Why?
| | Hematopoietic Stem Cell Transplantation | 10 | 2024 | 699 | 1.370 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 8 | 2025 | 195 | 1.270 |
Why?
| | Transplantation Conditioning | 10 | 2024 | 191 | 1.220 |
Why?
| | Skin Neoplasms | 6 | 2024 | 853 | 1.110 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2018 | 266 | 1.010 |
Why?
| | Lymphoma, Non-Hodgkin | 3 | 2023 | 124 | 1.000 |
Why?
| | Lymphoma, B-Cell | 5 | 2024 | 141 | 0.950 |
Why?
| | Hematopoietic Stem Cell Mobilization | 2 | 2017 | 28 | 0.910 |
Why?
| | Hodgkin Disease | 2 | 2018 | 172 | 0.900 |
Why?
| | Graft vs Host Disease | 6 | 2024 | 279 | 0.740 |
Why?
| | Smiling | 1 | 2021 | 6 | 0.710 |
Why?
| | Thrombocytopenia | 1 | 2023 | 204 | 0.690 |
Why?
| | DNA, Viral | 3 | 2017 | 356 | 0.650 |
Why?
| | Face | 1 | 2021 | 175 | 0.620 |
Why?
| | Cord Blood Stem Cell Transplantation | 4 | 2024 | 103 | 0.600 |
Why?
| | Natural Killer T-Cells | 1 | 2020 | 71 | 0.590 |
Why?
| | Hematology | 1 | 2019 | 21 | 0.570 |
Why?
| | Immunotherapy, Adoptive | 5 | 2025 | 343 | 0.560 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 244 | 0.540 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2024 | 1150 | 0.540 |
Why?
| | Heterocyclic Compounds | 2 | 2017 | 23 | 0.540 |
Why?
| | Prognosis | 9 | 2024 | 4330 | 0.500 |
Why?
| | Central Nervous System Neoplasms | 3 | 2024 | 177 | 0.500 |
Why?
| | Burkitt Lymphoma | 3 | 2021 | 61 | 0.480 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2017 | 992 | 0.480 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 198 | 0.460 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 1969 | 0.450 |
Why?
| | Antineoplastic Agents | 7 | 2023 | 2219 | 0.440 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 442 | 0.440 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2014 | 35 | 0.410 |
Why?
| | Antibodies, Monoclonal | 3 | 2023 | 1505 | 0.410 |
Why?
| | Viral Load | 1 | 2016 | 526 | 0.410 |
Why?
| | Rituximab | 7 | 2024 | 210 | 0.390 |
Why?
| | Remission Induction | 4 | 2024 | 306 | 0.390 |
Why?
| | Humans | 51 | 2025 | 145783 | 0.380 |
Why?
| | Antigens, CD19 | 4 | 2025 | 128 | 0.350 |
Why?
| | Adult | 24 | 2025 | 40881 | 0.350 |
Why?
| | Mycosis Fungoides | 2 | 2023 | 63 | 0.350 |
Why?
| | Mediastinal Neoplasms | 2 | 2025 | 53 | 0.340 |
Why?
| | Treatment Outcome | 14 | 2024 | 11794 | 0.330 |
Why?
| | Middle Aged | 24 | 2025 | 36309 | 0.310 |
Why?
| | Survival Analysis | 6 | 2020 | 1378 | 0.310 |
Why?
| | Transplantation, Homologous | 4 | 2019 | 419 | 0.300 |
Why?
| | Aged | 20 | 2025 | 26217 | 0.300 |
Why?
| | Immunoblastic Lymphadenopathy | 2 | 2022 | 2 | 0.300 |
Why?
| | Transplantation, Autologous | 3 | 2020 | 301 | 0.280 |
Why?
| | Aged, 80 and over | 10 | 2024 | 8347 | 0.280 |
Why?
| | Recurrence | 6 | 2024 | 1139 | 0.250 |
Why?
| | Salvage Therapy | 2 | 2019 | 165 | 0.250 |
Why?
| | Autografts | 2 | 2019 | 55 | 0.240 |
Why?
| | Anti-HIV Agents | 1 | 2014 | 912 | 0.240 |
Why?
| | Benzylamines | 2 | 2017 | 44 | 0.230 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 2 | 2015 | 19 | 0.230 |
Why?
| | Retrospective Studies | 12 | 2025 | 17330 | 0.220 |
Why?
| | Cyclophosphamide | 5 | 2024 | 272 | 0.220 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 23 | 0.210 |
Why?
| | Depsipeptides | 1 | 2024 | 15 | 0.200 |
Why?
| | Male | 22 | 2025 | 73011 | 0.200 |
Why?
| | Benzopyrans | 1 | 2024 | 30 | 0.200 |
Why?
| | Myeloablative Agonists | 2 | 2020 | 23 | 0.190 |
Why?
| | Sezary Syndrome | 1 | 2023 | 45 | 0.190 |
Why?
| | Immunotoxins | 1 | 2023 | 55 | 0.190 |
Why?
| | Purines | 1 | 2024 | 187 | 0.190 |
Why?
| | Female | 20 | 2025 | 79045 | 0.180 |
Why?
| | Disease-Free Survival | 3 | 2021 | 770 | 0.180 |
Why?
| | Etoposide | 4 | 2024 | 168 | 0.180 |
Why?
| | Young Adult | 11 | 2025 | 14254 | 0.180 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 218 | 0.180 |
Why?
| | T-Lymphocytes | 2 | 2020 | 1998 | 0.170 |
Why?
| | Allografts | 2 | 2020 | 152 | 0.160 |
Why?
| | Killer Cells, Natural | 2 | 2024 | 481 | 0.160 |
Why?
| | Doxorubicin | 4 | 2024 | 403 | 0.160 |
Why?
| | Prospective Studies | 4 | 2022 | 8078 | 0.150 |
Why?
| | Vincristine | 3 | 2024 | 144 | 0.140 |
Why?
| | Combined Modality Therapy | 3 | 2016 | 1271 | 0.140 |
Why?
| | Prednisone | 3 | 2024 | 226 | 0.140 |
Why?
| | Thiotepa | 1 | 2018 | 21 | 0.140 |
Why?
| | Lymphoproliferative Disorders | 1 | 2018 | 59 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 206 | 0.130 |
Why?
| | Central Nervous System Diseases | 1 | 2018 | 74 | 0.130 |
Why?
| | Antigens, CD34 | 1 | 2017 | 90 | 0.120 |
Why?
| | Asparaginase | 1 | 2016 | 32 | 0.120 |
Why?
| | Carcinogenesis | 1 | 2018 | 228 | 0.120 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2017 | 90 | 0.120 |
Why?
| | In Situ Hybridization | 1 | 2017 | 318 | 0.120 |
Why?
| | Biopsy | 2 | 2018 | 1082 | 0.120 |
Why?
| | Cell Count | 1 | 2017 | 319 | 0.120 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 735 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2019 | 883 | 0.120 |
Why?
| | North America | 1 | 2016 | 304 | 0.120 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2016 | 23 | 0.110 |
Why?
| | Europe | 1 | 2016 | 421 | 0.110 |
Why?
| | HIV Infections | 2 | 2021 | 3195 | 0.110 |
Why?
| | Neoplasm Staging | 2 | 2016 | 1475 | 0.110 |
Why?
| | Immunotherapy | 1 | 2020 | 668 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 838 | 0.110 |
Why?
| | Ohio | 1 | 2015 | 146 | 0.110 |
Why?
| | Biomarkers | 2 | 2016 | 4302 | 0.110 |
Why?
| | Drug Resistance | 1 | 2015 | 145 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2024 | 5428 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1582 | 0.100 |
Why?
| | Hematopoietic Stem Cells | 1 | 2017 | 435 | 0.100 |
Why?
| | B-Lymphocytes | 1 | 2018 | 872 | 0.090 |
Why?
| | Adolescent | 5 | 2024 | 22577 | 0.090 |
Why?
| | Registries | 4 | 2025 | 2410 | 0.090 |
Why?
| | Academic Medical Centers | 1 | 2015 | 554 | 0.090 |
Why?
| | Gene Expression | 1 | 2017 | 1478 | 0.090 |
Why?
| | Medicare | 1 | 2018 | 904 | 0.090 |
Why?
| | United States | 5 | 2023 | 16126 | 0.090 |
Why?
| | Genomics | 1 | 2017 | 830 | 0.090 |
Why?
| | Skin | 1 | 2016 | 754 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2023 | 169 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1450 | 0.080 |
Why?
| | Melphalan | 2 | 2020 | 43 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1777 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1329 | 0.080 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2024 | 118 | 0.080 |
Why?
| | Vidarabine | 2 | 2020 | 32 | 0.070 |
Why?
| | Whole-Body Irradiation | 2 | 2020 | 74 | 0.070 |
Why?
| | Fetal Blood | 2 | 2020 | 327 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2021 | 971 | 0.060 |
Why?
| | Cohort Studies | 3 | 2021 | 6033 | 0.060 |
Why?
| | Lactate Dehydrogenases | 1 | 2023 | 5 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2024 | 311 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2024 | 143 | 0.050 |
Why?
| | Disease Management | 2 | 2018 | 653 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 241 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2024 | 251 | 0.040 |
Why?
| | Interleukin-2 | 1 | 2023 | 440 | 0.040 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2021 | 112 | 0.040 |
Why?
| | Busulfan | 1 | 2020 | 15 | 0.040 |
Why?
| | Aminoquinolines | 1 | 2020 | 18 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 358 | 0.040 |
Why?
| | Carmustine | 1 | 2020 | 52 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2021 | 156 | 0.040 |
Why?
| | Cytarabine | 1 | 2020 | 66 | 0.040 |
Why?
| | Acetates | 1 | 2019 | 78 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 2094 | 0.040 |
Why?
| | Central Nervous System | 1 | 2021 | 282 | 0.040 |
Why?
| | Treatment Failure | 1 | 2020 | 360 | 0.040 |
Why?
| | Viral Tropism | 1 | 2018 | 36 | 0.030 |
Why?
| | Pilot Projects | 1 | 2024 | 1898 | 0.030 |
Why?
| | Ganciclovir | 1 | 2018 | 53 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2020 | 268 | 0.030 |
Why?
| | Quinazolines | 1 | 2019 | 266 | 0.030 |
Why?
| | Virus Latency | 1 | 2018 | 90 | 0.030 |
Why?
| | Zidovudine | 1 | 2018 | 77 | 0.030 |
Why?
| | Virus Activation | 1 | 2018 | 94 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2019 | 189 | 0.030 |
Why?
| | Standard of Care | 1 | 2016 | 81 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2020 | 1547 | 0.030 |
Why?
| | Dexamethasone | 1 | 2018 | 365 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1261 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 343 | 0.030 |
Why?
| | Receptors, Interleukin-6 | 1 | 2015 | 48 | 0.030 |
Why?
| | Organ Transplantation | 1 | 2018 | 253 | 0.030 |
Why?
| | Steroids | 1 | 2015 | 160 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1723 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2019 | 769 | 0.020 |
Why?
| | Mice | 2 | 2023 | 18356 | 0.020 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 364 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1491 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2018 | 3130 | 0.020 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2018 | 688 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1512 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3346 | 0.020 |
Why?
| | Biomedical Research | 1 | 2016 | 719 | 0.020 |
Why?
| | Risk Factors | 1 | 2024 | 10919 | 0.020 |
Why?
| | Animals | 2 | 2023 | 38102 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2018 | 4568 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2770 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3752 | 0.020 |
Why?
| | Child | 1 | 2024 | 22740 | 0.010 |
Why?
|
|
Haverkos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|